The House on November 30 approved the 21st Century Cures Act , 392-26, amended by a Manager’s Amendment submitted by House Energy and Commerce Chair Fred Upton (R-Mich.). While the Manager’s Amendment modifies slightly the allocation of funding in the NIH Innovation Account on an annual basis, it maintains the overall level of funding in the Account at a total of $4.796 billion between FYs 2017 and 2026. For the Precision Medicine Initiative, the Amendment provides $1.455 billion between FYs 2017 and 2026; for BRAIN, $1.511 billion between FYs 2017 and 2026; for cancer research, $1.8 billion between FYs 2017 and 2023; and for clinical research to advance regenerative medicine using adult stem cells, the Amendment provides $30 million between FYs 2017 and 2020.
Committee materials, bill text, list of supporting organizations, and the Manager’s Amendment and other materials are available at the following links:
Last updated: December 1, 2016